ic070077p_si_016.cif (30.74 kB)
Download fileMO Tripeptide Diastereomers (M = 99/99mTc, Re): Models To Identify the Structure of 99mTc Peptide Targeted Radiopharmaceuticals
dataset
posted on 2007-09-03, 00:00 authored by Melchor V. Cantorias, Robertha C. Howell, Louis Todaro, John E. Cyr, Dietmar Berndorff, Robin D. Rogers, Lynn C. FrancesconiBiologically active molecules, such as many peptides, serve as targeting vectors for radiopharmaceuticals based
on 99mTc. Tripeptides can be suitable chelates and are easily and conveniently synthesized and linked to peptide
targeting vectors through solid-phase peptide synthesis and form stable TcVO complexes. Upon complexation with
[TcO]3+, two products form; these are syn and anti diastereomers, and they often have different biological behavior.
This is the case with the approved radiopharmaceutical [99mTcO]depreotide ([99mTcO]P829, NeoTect) that is used
to image lung cancer. [99mTcO]depreotide indeed exhibits two product peaks in its HPLC profile, but assignment of
the product peaks to the diastereomers has proven to be difficult because the metal peptide complex is difficult to
crystallize for structural analysis. In this study, we isolated diastereomers of [99TcO] and [ReO] complexes of several
tripeptide ligands that model the metal chelator region of [99mTcO]depreotide. Using X-ray crystallography, we observed
that the early eluting peak (A) corresponds to the anti diastereomer, where the TcO group is on the opposite
side of the plane formed by the ligand backbone relative to the pendant groups of the tripeptide ligand, and the
later eluting peak (B) corresponds to the syn diastereomer, where the TcO group is on the same side of the
plane as the residues of the tripeptide. 1H NMR and circular dichroism (CD) spectroscopy report on the metal
environment and prove to be diagnostic for syn or anti diastereomers, and we identified characteristic features
from these techniques that can be used to assign the diastereomer profile in 99mTc peptide radiopharmaceuticals
like [99mTcO]depreotide and in 188Re peptide radiotherapeutic agents. Crystallography, potentiometric titration, and
NMR results presented insights into the chemistry occurring under physiological conditions. The tripeptide complexes
where lysine is the second amino acid crystallized in a deprotonated metallo-amide form, possessing a short N1−M
bond. The pKa measurements of the N1 amine (pKa ∼5.6) suggested that this amine is rendered more acidic by
both metal complexation and the presence of the lysine residue. Furthermore, peptide chelators incorporating a
lysine (like the chelator of [TcO]depreotide) likely exist in the deprotonated form in vivo, comprising a neutral metal
center. Deprotonation possibly mediates the interconversion process between the syn and anti diastereomers. The
N1 amine group on non-lysine-containing metallopeptides is not as acidic (pKa ∼6.8) and does not deprotonate
and crystallize as do the metallo-amide species. Three of the tripeptide ligands (FGC, FSC, and FKC) were
radiolabeled with 99mTc, and the individual syn and anti isomers were isolated for biodistribution studies in normal
female nude mice. The main organs of uptake were the liver, intestines, and kidneys, with the FGC compounds
exhibiting the highest liver uptake. In comparing the diastereomers, the syn compounds had substantially higher
organ uptake and slower blood clearance than the anti compounds.
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
FSCp KHPLCFGC99 m Tc peptide radiopharmaceuticalsdiastereomerproduct peaksN 1 aminemo Tripeptide Diastereomerstripeptide ligands99 m Tc Peptide Targeted Radiopharmaceuticals Biologically1 H NMRFKCTcOeluting peakimage lung cancerN 1 amine group188 Re peptide radiotherapeutic agentsmetal chelator regionTc V O complexes99 m Tcsyn